PCSK9 Inhibitor Price Reductions and Medicare Part D Utilization and Spending

This cross-sectional study evaluates price reductions and subsequent Medicare Part D utilization and spending for proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.

Corresponding Author: Jalpa A. Doshi, PhD, University of Pennsylvania, 3600 Civic Center Blvd, Philadelphia, PA 19104 (jdoshi@pennmedicine.upenn.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.